You are here

FDA Repeats Plavix Warning

October 20, 2010 -- The Food and Drug Administration said it plans to reiterate its warning that patients taking the anticlotting drug Plavix should avoid also taking the heartburn drug Prilosec, despite a new study that didn't find evidence the interaction was dangerous.

"We are absolutely not" changing earlier warnings to doctors and patients against taking the drugs together, said Mary Ross Southworth, an FDA official overseeing the safety of cardiovascular products.

A series of studies since 2008 have indicated that the drug combination can cut in half Plavix's ability to prevent blood clots, according to the FDA. Earlier this month, however, a randomized trial called Cogent published in the New England Journal of Medicine suggested patients taking both drugs were at no greater risk of serious cardiovascular events than those taking Plavix alone.

The full story is available on the Wall Street Journal Web site.

Recent Headlines

Medical Device Enables Nerve Stimulation During Sleep
May Offer Improved Safety Profile for Pediatric Patients
Hope for Sufferers With Post-Treatment Lyme Disease Syndrome
KardiaMobile Receives Two More Clearances for Arrhythmia Detection
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable